Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821080 · ClinicalTrials.gov registry record · Phase 1
Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00821080: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00821080 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00821080, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study is evaluating a combination of drugs called sirolimus and vandetanib to treat glioblastoma. Sirolimus has been approved for use in patients who undergo organ transplants. Sirolimus works by suppressing the immune system so the body will not reject the transplanted organ. Vandetanib is an investigational drug and we are trying to find the highest and safest dose of vandetanib with sirolimus that can be given safely.
Interventions
- DRUG Sirolimus
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00821080
The ClinicalTrials.gov registry entry for NCT00821080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT00821080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00821080 about?
NCT00821080 is a clinical study titled "Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma". This study is evaluating a combination of drugs called sirolimus and vandetanib to treat glioblastoma. Sirolimus has been approved for use in patients who undergo organ transplants. Sirolimus works by suppressing the immune system so the body will not reject the transplanted organ. Vandetanib is an ...
What is the current status of trial NCT00821080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2008-10. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00821080?
The interventions under investigation include: Sirolimus (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00821080?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.